Health
Virus drug benefit only marginal: study – Shepparton News
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.The 600-patient analysis, published on Friday by the Journal of the American Medical …
-
General14 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News23 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General14 hours agoOf saints and sinners | The Spectator Australia
-
Noosa News19 hours agoBrisbane rising on global rankings, but still behind southern capitals